

Gianluigi Savarese

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1308202/gianluigi-savarese-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156
papers

4,421
citations

31
h-index

62
g-index

206
ext. papers

6,428
ext. citations

6.7
avg, IF

5.8
L-index

#	Paper	IF	Citations
156	Global Public Health Burden of Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 7-11	4.2	996
155	Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1192-201	15.1	178
154	Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. <i>European Heart Journal</i> , 2015 , 36, 3392-403	9.5	145
153	Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2090-9	15.1	141
152	Gender differences in the effects of cardiovascular drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 163-182	6.4	126
151	A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 131-42	15.1	126
150	Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. <i>PLoS ONE</i> , 2013 , 8, e58287	3.7	118
149	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1624-1634	12.3	113
148	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	104
147	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1326-1334	12.3	86
146	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 181, 239-44	3.2	82
145	The role of metabolic syndrome in heart failure. <i>European Heart Journal</i> , 2015 , 36, 2630-4	9.5	66
144	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 180-188	6.4	65
143	Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. <i>JACC: Heart Failure</i> , 2014 , 2, 148-58	7.9	59
142	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 306-317	7.9	54
141	Safety and efficacy of ezetimibe: A meta-analysis. <i>International Journal of Cardiology</i> , 2015 , 201, 247-52	3.2	54
140	Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. <i>Diabetes Care</i> , 2013 , 36, 2395-401	14.6	54

139	The prognostic value of normal stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a meta-analysis. <i>Circulation: Cardiovascular Imaging</i> , 2013 , 6, 574-82	3.9	53
138	Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. <i>JACC: Heart Failure</i> , 2019 , 7, 505-515	7.9	50
137	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016 , 220, 595-601	3.2	50
136	Takotsubo cardiomyopathy: overview. <i>Heart Failure Clinics</i> , 2013 , 9, 249-66, x	3.3	47
135	Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke. <i>European Heart Journal</i> , 2015 , 36, 1590-600	9.5	47
134	Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1199-206	8.8	44
133	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. <i>Circulation</i> , 2019 , 140, 1530-1539	16.7	41
132	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
131	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. <i>JACC: Heart Failure</i> , 2016 , 4, 870-880	7.9	41
130	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 700-710	9.5	35
129	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019 , 139, 1458-1460	16.7	34
128	Changes in serum uric acid levels and cardiovascular events: a meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, 707-14	4.5	34
127	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1378-1389	12.3	32
126	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 65-76	7.9	32
125	Sex Differences in Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1065, 529-544	3.6	30
124	Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 2482-9	3.2	29
123	Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries: a digital reactive hyperemia study. <i>International Journal of Cardiology</i> , 2013 , 165, 67-71	3.2	29
122	Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2013 , 42, 414-24	13.6	29

121	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. <i>International Journal of Cardiology</i> , 2014 , 172, 403-10	3.2	28
120	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021 , 23, 906-914	12.3	28
119	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 471-479	12.3	26
118	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 10, 174-180	6.4	26
117	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	25
116	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. <i>Upsala Journal of Medical Sciences</i> , 2019 , 124, 65-69	2.8	25
115	Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e52952	3.7	25
114	Expert Review on the Prognostic Role of Echocardiography after Acute Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2017 , 30, 431-443.e2	5.8	24
113	Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2015 , 16, 1148-53	4.1	24
112	Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc. <i>International Journal of Cardiology</i> , 2014 , 175, 446-50	3.2	24
111	Global burden of heart failure: A comprehensive and updated review of epidemiology.. <i>Cardiovascular Research</i> , 2022 ,	9.9	24
110	Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 476-485	12.3	24
109	Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2019 , 8, e011737	6	23
108	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2018 , 39, 4257-4265	9.5	23
107	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018 , 6, 246-256	7.9	22
106	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 230-236	6.4	22
105	Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. <i>Heart</i> , 2011 , 97, 1828-33	5.1	22
104	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019 , 21, 1383-1397	12.3	20

103	The Impact of Social and Cultural Engagement and Dieting on Well-Being and Resilience in a Group of Residents in the Metropolitan Area of Naples. <i>Journal of Aging Research</i> , 2016 , 2016, 4768420	2.3	20
102	Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017 , 312, H232-H238	5.2	19
101	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018 , 24, 365-374	3.3	19
100	Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 169, 262-70	3.2	19
99	Prognostic role of myocardial single photon emission computed tomography in the elderly. <i>Journal of Nuclear Cardiology</i> , 2010 , 17, 310-5	2.1	19
98	ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. <i>International Journal of Cardiology</i> , 2016 , 217, 128-34	3.2	19
97	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. <i>Heart</i> , 2018 , 104, 1093-1100	5.1	18
96	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2020 , 298, 59-65	3.2	18
95	Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. <i>International Journal of Cardiology</i> , 2013 , 167, 2757-64	3.2	17
94	Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. <i>Cardiovascular Research</i> , 2017 , 113, 61-69	9.9	17
93	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 1081-1088	4.5	16
92	Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 2040-9	8.8	16
91	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	16
90	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1390-1398 ¹⁵	12.3	15
89	Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 103-112	12.3	15
88	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal -</i>	6.4	15
87	Prognostic impact of metabolic syndrome in patients with chronic heart failure: data from GISSI-HF trial. <i>International Journal of Cardiology</i> , 2015 , 178, 85-90	3.2	14
86	Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. <i>Heart Failure Reviews</i> , 2015 , 20, 305-16	5	14

85	Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	14
84	N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction. <i>European Journal of Echocardiography</i> , 2011 , 12, 506-13		14
83	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 104-114	6.4	14
82	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1394-1405	6.1	13
81	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). <i>European Journal of Heart Failure</i> , 2021 , 23, 1499-1511 ^{12,13}	12.3	11 ¹³
80	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018 , 39, 2274-2281	9.5	12
79	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021 , 23, 1260-1275	12.3	12
78	Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with lower limbs arterial disease. <i>Atherosclerosis</i> , 2013 , 228, 386-9	3.1	11
77	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 973-982	12.3	11
76	Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 2233-2245 ^{7,8}	7.3	10
75	Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 177-84	7	10
74	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021 , 23, 1012-1022 ^{12,13}	12.3	10 ¹⁰
73	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020 , 313, 76-82	3.2	9
72	Is ejection fraction in heart failure a limitation or an opportunity?. <i>European Journal of Heart Failure</i> , 2018 , 20, 431-432	12.3	9
71	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 218-28	6.4	9
70	Clinical and research implications of serum versus plasma potassium measurements. <i>European Journal of Heart Failure</i> , 2019 , 21, 536-537	12.3	9
69	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021 , 8, 1295-1303	3.7	9
68	Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. <i>European Heart Journal</i> , 2017 , 38, 916-919	9.5	8

67	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2019 , 287, 66-72	3.2	8
66	Nuclear assessment of right ventricle. <i>Echocardiography</i> , 2015 , 32 Suppl 1, S69-74	1.5	8
65	Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification. <i>European Heart Journal Cardiovascular Imaging</i> , 2012 , 13, 453-8	4.1	8
64	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. <i>Heart</i> , 2021 , 107, 229-236	5.1	8
63	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021 , 23, 1844-1854	12.3	8
62	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015 , 199, 415-23	3.2	7
61	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 1806-1818	12.3	7
60	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. <i>European Journal of Heart Failure</i> , 2021 , 23, 1698-1707	12.3	7
59	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019 , 6, 830-839	3.7	6
58	Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. <i>International Journal of Cardiology</i> , 2014 , 177, 152-60	3.2	6
57	Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology. <i>Current Cardiology Reports</i> , 2020 , 22, 102	4.2	6
56	Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	6
55	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020 , 7, 3438	3.7	6
54	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 55-56	6.4	6
53	Cardiac magnetic resonance for the assessment of myocardial viability: from pathophysiology to clinical practice. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 862-9	1.9	5
52	Tai Chi and Qigong Practices for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020 , 2020, 2034625	2.3	5
51	The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	5
50	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. <i>Cardiovascular Research</i> , 2021 ,	9.9	5

49	A registry-based algorithm to predict ejection fraction in patients with heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2388-2397	3.7	4
48	Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis. <i>International Journal of Cardiology</i> , 2020 , 307, 75-81	3.2	4
47	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	4
46	Drug Layering in Heart Failure: Phenotype-Guided Initiation. <i>JACC: Heart Failure</i> , 2021 , 9, 775-783	7.9	4
45	Association Between β -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2020 , 13, e007180	7.6	4
44	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 97-103	6.4	4
43	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021 , 27, 888-895	3.3	4
42	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021 , 23, 1942-1951	12.3	4
41	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	4
40	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017 , 226, 65-70	3.2	3
39	Reply: benefits of statins in healthy elderly subjects: what is the number needed to treat?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2303	15.1	3
38	Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022 ,	6.4	3
37	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , 2020 , 41, 3419-3420	9.5	3
36	Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. <i>Journal of Internal Medicine</i> , 2021 , 289, 369-384	10.8	3
35	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	2
34	Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2019 , 5, 70-73	4.2	2
33	Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 277-279	6.4	2
32	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 557-567	6.4	2

31	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. <i>Diabetes Research and Clinical Practice</i> , 2021 , 175, 108796	7.4	2
30	Incretin-based therapy for type 2 diabetes: A real class effect?. <i>International Journal of Cardiology</i> , 2017 , 227, 141-142	3.2	1
29	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 453-459	6.4	1
28	Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry". <i>Circulation</i> , 2020 , 141, e648-e649	16.7	1
27	Reply to: Ezetimibe: A real effect?. <i>International Journal of Cardiology</i> , 2016 , 209, 337-8	3.2	1
26	Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case. <i>Journal of Cardiology Cases</i> , 2012 , 5, e166-e170	0.6	1
25	An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications.. <i>Heart Failure Reviews</i> , 2022 , 1	5	1
24	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. <i>ESC Heart Failure</i> , 2021 , 9, 164	3.7	1
23	Association Between β Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1165-1174	3.3	1
22	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle <i>Do no harm</i> ?. <i>European Journal of Heart Failure</i> , 2021 , 23, 1068-1075	12.3	1
21	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study. <i>ESC Heart Failure</i> , 2021 , 8, 4243-4254	3.7	1
20	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. <i>European Journal of Internal Medicine</i> , 2021 , 90, 10-15	3.9	1
19	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2021 ,	3.9	1
18	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e89-e90	6.4	1
17	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021 , 343, 63-72	3.2	1
16	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
15	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction.. <i>Cardiac Failure Review</i> , 2022 , 8, e16	4.2	1
14	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022 , 346, 30-34	3.2	0

13	The tight tie of MAG versus SAG in CABG. <i>International Journal of Cardiology</i> , 2021 , 323, 26	3.2	o
12	PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e88	6.4	o
11	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022 , 10, 380-392	7.9	o
10	Reply: Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 533-534	7.9	
9	Endogenous sex hormones are associated with blood pressure change and hypertension incidence in postmenopausal women. <i>Clinical Lipidology</i> , 2012 , 7, 617-620		
8	Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. <i>European Heart Journal</i> , 2013 , 34, P5728-P5728	9.5	
7	Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States between 2005-2018.. <i>American Journal of the Medical Sciences</i> , 2022 ,	2.2	
6	Methodological issues in meta-analyses of real-world clinical data to infer causality. <i>International Journal of Cardiology</i> , 2021 , 345, 107-108	3.2	
5	Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?. <i>European Cardiology Review</i> , 2019 , 14, 139-140	3.9	
4	New evidence from the scientific sessions 2020 of the American Heart Association. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e1	6.4	
3	Iron deficiency in heart failure. <i>International Journal of Cardiology</i> , 2020 , 299, 207	3.2	
2	Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2016 , 212, 198-200	3.2	
1	Sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e9-e10	6.4	